![Yann Echelard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yann Echelard
Direktor/Vorstandsmitglied bei
TG THERAPEUTICS, INC.
Vermögen: 12 Mio $ am 30.06.2026
Profil
Yann Echelard is the founder of Ampersand Biomedicines, Inc., founded in 2021, serving as Founding President.
Dr. Echelard was the founder of Profound Therapeutics, Inc., founded in 2019, serving as President.
Dr. Echelard is also the founder of Laronde, Inc...
Dr. Echelard is an Independent Director at TG Therapeutics, Inc. since 2012.
Dr. Echelard is a Director at LFB USA, Inc. Dr. Echelard is a Director at Hema Biologics.
Dr. Echelard is an Operating Partner at Flagship Pioneering, LLC since 2018.
Dr. Echelard is a Partner at ORI Capital Ltd. starting in 2026.
Dr. Echelard was President, Chief Executive Officer & Director at rEVO Biologics, Inc. from 2012 to 2018.
Dr. Echelard was Vice President-Research & Development at GTC Biotherapeutics UK Ltd. Dr. Echelard was Founding President at Ring Therapeutics, Inc. Dr. Echelard was Founding President at Cellarity Inc. Dr. Echelard earned a doctorate from the University of Montréal.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.06.2026 | 223’816 ( 0.15% ) | 12 Mio $ | 30.06.2026 |
Aktive Positionen von Yann Echelard
| Unternehmen | Position | Beginn |
|---|---|---|
| TG THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 09.11.2012 |
Hema Biologics
 Hema Biologics Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Direktor/Vorstandsmitglied | - |
LFB USA, Inc.
 LFB USA, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicinal products | Direktor/Vorstandsmitglied | - |
Flagship Pioneering, Inc.
 Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Private Equity Investor | 01.10.2018 |
Ampersand Biomedicines
 Ampersand Biomedicines BiotechnologyHealth Technology Develops and manufactures medicines | Gründer | 01.01.2021 |
ORI Capital Investment Advisory Hong Kong Ltd.
 ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Private Equity Investor | 01.07.2026 |
Ehemalige bekannte Positionen von Yann Echelard
| Unternehmen | Position | Ende |
|---|---|---|
| REVO BIOLOGICS INC | Vorstandsvorsitzender | 01.04.2018 |
GTC Biotherapeutics UK Ltd. | Direktor/Vorstandsmitglied | 01.12.2010 |
Profound Therapeutics
 Profound Therapeutics Pharmaceuticals: OtherHealth Technology Develops human proteome therapeutics discovery services | Gründer | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Yann Echelard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
80
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
TG Therapeutics, Inc.
 TG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Finance |
University of Montréal
 University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions | Health Technology |
LFB USA, Inc.
LFB USA, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicinal products | Health Technology |
GTC Biotherapeutics UK Ltd. | |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Finance |
Hema Biologics
Hema Biologics Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops transforming commensal viruses therapies | Health Technology |
Cellarity Inc.
 Cellarity Inc. Packaged SoftwareTechnology Services Develops AI-driven platform for drug delivery | Technology Services |
Laronde Inc.
 Laronde Inc. Miscellaneous Commercial ServicesCommercial Services Develops an eRNA therapeutic platform that capable diverse proteins inside body | Commercial Services |
Profound Therapeutics
Profound Therapeutics Pharmaceuticals: OtherHealth Technology Develops human proteome therapeutics discovery services | Health Technology |
Ampersand Biomedicines
Ampersand Biomedicines BiotechnologyHealth Technology Develops and manufactures medicines | Health Technology |
